Caris Life Sciences, Inc. is 1.9x more valuable than GRAIL, LLC by market capitalization ($4.85 B vs $2.51 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | GRAL | CAI |
|---|---|---|
| Market cap | $2.51 B | $4.85 B |
| US-listed rank | #1943 | #1404 |
| Revenue (latest FY) | $147.17M | $812.03M |
| Net income (latest FY) | -$408.35M | -$68.09M |
| Net margin | -277.5% | -8.4% |
| SEC filings | 228 | 102 |
Caris Life Sciences, Inc. is 1.9x more valuable than GRAIL, LLC by market capitalization ($4.85 B vs $2.51 B).
In their latest fiscal years, GRAIL, LLC reported $147.17M in revenue while Caris Life Sciences, Inc. reported $812.03M.
Full pages: GRAIL, LLC and Caris Life Sciences, Inc., or browse the full rankings.